Kurs
-11,11%
Likviditet
0,73 MSEK
Kalender
| Est. tid* | ||
| 2026-02-25 | 08:20 | Bokslutskommuniké 2025 |
| 2025-11-06 | 08:20 | Kvartalsrapport 2025-Q3 |
| 2025-08-13 | 08:20 | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-21 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2025-05-20 | - | Årsstämma |
| 2025-02-28 | - | Bokslutskommuniké 2024 |
| 2025-01-07 | - | Extra Bolagsstämma 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2024-05-21 | - | Årsstämma |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2024-01-11 | - | Extra Bolagsstämma 2023 |
| 2023-10-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-11 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-21 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2023-04-20 | - | Årsstämma |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2023-01-09 | - | Extra Bolagsstämma 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-12-16 | - | Extra Bolagsstämma 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-10 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2021-05-27 | - | Årsstämma |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-10 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-28 | - | Extra Bolagsstämma 2020 |
| 2020-06-30 | - | Årsstämma |
| 2020-06-17 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-16 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-20 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2019-06-19 | - | Årsstämma |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-09 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-17 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-29 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2018-03-28 | - | Årsstämma |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-17 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-19 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2017-05-18 | - | Årsstämma |
| 2017-05-16 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-27 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-07-22 | - | Extra Bolagsstämma 2016 |
| 2016-05-20 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2016-05-19 | - | Årsstämma |
| 2016-05-17 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-19 | - | Extra Bolagsstämma 2015 |
| 2015-11-11 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-17 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-08 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-10 | - | X-dag ordinarie utdelning PMED 0.00 SEK |
| 2015-04-09 | - | Årsstämma |
| 2015-02-27 | - | Bokslutskommuniké 2014 |
| 2014-10-15 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-13 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Peptonic Medical AB (publ) ("Peptonic" or the "Company") announces that the Uppsala District Court has today, June 17 2025, approved the Company's request to extend the ongoing company reconstruction by three months, until 15 September 2025. The extension is in line with the previously communicated timeline and aims to allow finalization of a reconstruction plan and the initiation of plan proceedings in accordance with the Swedish Company Reconstruction Act.
Uppsala District Court has today approved the Company's request to extend the ongoing company reconstruction by three months, until 15 September 2025. The request, submitted on 8 June 2025, aligns with the earlier communicated plan, under which the reconstruction is expected to be completed within three to six months from the application date. During the extension period, the Company intends to finalize the reconstruction plan, negotiate with relevant stakeholders, and initiate formal plan proceedings under the Company Reconstruction Act. In parallel, the Company continues to pursue its key commercial initiatives in the Nordic and U.S. markets.
The Board of Directors believes that the planned reconstruction measures, including a direct share issue and set-off issues, are necessary and sufficient to restore the Company's financial stability and ensure continued operations.
For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic Medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.